Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29134195 | 0.89 | GRM5 (0.36) | GRM5S1PR5CYP1A2HRH4 | |
| SCHEMBL26171964 | 0.89 | GRM5 (0.36) | GRM5S1PR5CYP1A2HRH4 | |
| SCHEMBL24801556 | 0.87 | S1PR5 (0.37) | GRM5S1PR5CYP1A2HRH4 | |
| SCHEMBL26171399 | 0.87 | S1PR5 (0.46) | GRM5S1PR5CYP1A2 | |
| SCHEMBL29021196 | 0.86 | ALDH1A1 (0.41) | GRM5HRH4 | |
| SCHEMBL31631085 | 0.86 | NR1H4 (0.34) | GRM5LMNAHRH4 | |
| SCHEMBL29021233 | 0.83 | HRH4 (0.38) | GRM5HRH4 | |
| SCHEMBL26087526 | 0.83 | LMNA (0.34) | GRM5CTSLCTSBCTSKNAAA | |
| SCHEMBL30511792 | 0.83 | MYC (0.38) | GRM5 | |
| SCHEMBL26171398 | 0.83 | S1PR5 (0.39) | GRM5S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720071-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | Beone Medicines I GmbH (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-20250332266-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE SWITZERLAND GMBH (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4615850-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BeiGene Switzerland GmbH (CH) | 2025-09-17 | — | — | EP | disclosed |
| US-20250195513-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2025-06-19 | — | — | US | disclosed |
| EP-4536664-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BeiGene, Ltd. (KY) | 2025-04-16 | — | — | EP | disclosed |
| CN-119403805-A | Degradation of IRAK4 by conjugation of IRAK4 inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20240425523-A1 | Compounds for the Degradation of EGFR Kinase | BEONE MEDICINES I GMBH (CH) | 2024-12-26 | — | — | US | disclosed |
| WO-2024246838-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE SWITZERLAND GMBH (CH) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024099395-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE, LTD. (KY) | 2024-05-16 | — | — | WO | disclosed |
| WO-2023237049-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425523-A1 | Compounds for the Degradation of EGFR Kinase | EGFR, ERBB2, ERBB3 | GRM5 3078/4885CTSL 2717/4885CTSB 1710/4885 |
| US-20250195513-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | IRAK4, IRAK2, IRAK3 | GRM5 2859/4885CTSL 3212/4885CTSB 3206/4885 |
| US-20250332266-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | EGFR, ERBB2, ERBB3 | GRM5 3226/4885CTSL 3071/4885CTSB 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.